心血管

订阅

MedSci主页 / 所有栏目 / 心血管

Heart：远隔缺血后适应不减轻PCI相关性损伤

2013-07-17 MedSci Heart

PCI远隔缺血后适应
关注

西班牙一项研究表明，远隔缺血后适应（RIP）未能减轻择期经皮冠脉介入（PCI）相关性损伤，并且接受RIP治疗的糖尿病患者PCI相关性心肌梗死（PCI-MI）发生率更高。论文7月12日在线发表于《心脏》（Heart）。 此项研究共纳入232例因稳定或不稳定心绞痛而接受择期PCI的患者，并随机给予RIP或安慰剂治疗。主要转归指标为24小时肌钙蛋白I峰浓度；次要转归指标为住院治疗、因稳定性心绞痛或急性

西班牙一项研究表明，远隔缺血后适应（RIP）未能减轻择期经皮冠脉介入（PCI）相关性损伤，并且接受RIP治疗的糖尿病患者PCI相关性心肌梗死（PCI-MI）发生率更高。论文7月12日在线发表于《心脏》（Heart）。

此项研究共纳入232例因稳定或不稳定心绞痛而接受择期PCI的患者，并随机给予RIP或安慰剂治疗。主要转归指标为24小时肌钙蛋白I峰浓度；次要转归指标为住院治疗、因稳定性心绞痛或急性冠脉综合征行PCI以及随访1年后死亡率。对应用RIP的糖尿病患者进行特别研究。

结果显示，受试者平均年龄为64.6岁，42%伴有糖尿病。RIP和对照组患者的肌钙蛋白峰值分别为0.476和0.478 ng/mL（P=0.99），PCI-MI发生率分别为36%和30.8%（P=0.378）。糖尿病RIP患者的PCI-MI发生率更高（OR 2.7；P=0.027）。RIP和安慰剂组的次要转归发生率分别为11.7%和10.8%（P=0.907）。

原始出处：

Carrasco-Chinchilla F, Muñoz-García AJ, Domínguez-Franco A, Millán-Vázquez G, Guerrero-Molina A, Ortiz-García C, Enguix-Armada A, Alonso-Briales JH, Hernández-García JM, de Teresa-Galván E, Jiménez-Navarro MF.Remote ischaemic postconditioning: does it protect against ischaemic damage in percutaneous coronary revascularisation? Randomised placebo-controlled clinical trial.Heart. 2013 Jul 12.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1837121, encodeId=2885183e1217a, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Jun 01 05:47:00 CST 2014, time=2014-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355780, encodeId=b50d1355e8044, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 19 00:47:00 CST 2013, time=2013-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396771, encodeId=fbc21396e71dc, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jul 19 00:47:00 CST 2013, time=2013-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562177, encodeId=cd6015621e7d1, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Jul 19 00:47:00 CST 2013, time=2013-07-19, status=1, ipAttribution=)]
    2014-06-01 shenxlcyp

    #相关性#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1837121, encodeId=2885183e1217a, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Jun 01 05:47:00 CST 2014, time=2014-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355780, encodeId=b50d1355e8044, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 19 00:47:00 CST 2013, time=2013-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396771, encodeId=fbc21396e71dc, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jul 19 00:47:00 CST 2013, time=2013-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562177, encodeId=cd6015621e7d1, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Jul 19 00:47:00 CST 2013, time=2013-07-19, status=1, ipAttribution=)]
    2013-07-19 zhaojie88

    #ART#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1837121, encodeId=2885183e1217a, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Jun 01 05:47:00 CST 2014, time=2014-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355780, encodeId=b50d1355e8044, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 19 00:47:00 CST 2013, time=2013-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396771, encodeId=fbc21396e71dc, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jul 19 00:47:00 CST 2013, time=2013-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562177, encodeId=cd6015621e7d1, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Jul 19 00:47:00 CST 2013, time=2013-07-19, status=1, ipAttribution=)]
    2013-07-19 智者为医08

    #损伤#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1837121, encodeId=2885183e1217a, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Jun 01 05:47:00 CST 2014, time=2014-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355780, encodeId=b50d1355e8044, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 19 00:47:00 CST 2013, time=2013-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396771, encodeId=fbc21396e71dc, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jul 19 00:47:00 CST 2013, time=2013-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562177, encodeId=cd6015621e7d1, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Jul 19 00:47:00 CST 2013, time=2013-07-19, status=1, ipAttribution=)]
    2013-07-19 slcumt

    #HEART#

    0

相关资讯

Circulation：贝叶斯方法确认PCI能改善无保护左主干病变患者生存

    一些临床试验支持无保护左主干病变的患者接受冠脉搭桥治疗（CABG）。也有研究认为对此适应症经皮冠状动脉介入治疗（PCI）治疗和CABG有同等治疗作用，间接支持了2011年ACC/AHA指南对改善无保护左主干病变患者PCI治疗的IIa级推荐。研究人员采用贝叶斯方法验证是否支持这一新治疗建议。该文发表在2013年6月4日的Circulation杂志上。 

NEJM：无现场心脏外科准备不会对非紧急PCI产生影响

急诊手术已变成一种经皮冠脉介入术（PCI）后并不常见的处理事件。PCI期间和之后现场可提供心脏外科对确保可能的最佳转归的意义尚不明确。美国波士顿大学医学中心心血管科Alice K. Jacobs博士等人进行了深入研究，他们发现，在不能提供现场心脏外科的马萨诸塞州医院进行的非紧急PCI操作其30天和1年时临床事件发生率方面不劣于有现场心脏外科医院进行的操作。相关论文发表于国际权威杂志NEJM 近期在

Am J Cardiol：老年慢性完全闭塞病变患者行PCI可改善生存

　　日本一项研究表明，在老年患者中，因慢性完全闭塞病变（CTO）而实施的经皮冠状动脉介入（PCI）操作的成功率较高，并且可改善心脏性生存率。论文于6月3日在线发表于《美国心脏病学杂志》（Am J Cardiol）。 　　此项观察性研究共纳入284例因CTO接受PCI治疗的患者，并回顾性对比评估≥75岁老年组（67例）和<75岁年轻组（217例）患者的相关特征。 　　结

Circulation：荟萃分析显示PCI减少心梗死亡率与减少自发性心梗呈平行关系

已有很多研究证实自发性心肌梗死（与再血管化治疗无关的心肌梗死）始终与死亡相关。PCI手术会引发包括心梗在内的相关并发症，但早先的研究发现围PCI手术期间发生的心肌梗死死亡率很低。由于研究人群、生物标记物测定、围PCI心梗定义的不同，围PCI心梗的发生率有很大不同，最高达50%，对围PCI心梗的临床预测价值有很大争议。另外，PCI术后生物标记升高值的容许范围及其临床预测价值也存在很大争议。研究者试图

CCI：达比加群并不能减少STEMI后行直接PCI术患者的梗死面积

HIRIZON-AMI研究是一项大型、前瞻性、随机的急性心肌梗死患者接受再血管化治疗和支架的预后研究。在这项研究中比较了在ST段抬高性心肌梗死患者在直接PCI术后，使用直接凝血酶原抑制剂达比加群与普通肝素加糖蛋白IIb/IIIa受体拮抗剂对全因死亡率和心血管死亡的影响。由于减少大出血事件方面的效应，达比加群组的死亡率较低。但对STEMI患者而言，心肌梗死面积是除了大出血之外的一项影响预后的重要因素

JACC：一站式复合冠状动脉血运重建术与CABG，PCI对比用于多支血管病变的三年随访结果

北京阜外医院最近一项临床研究，比较一站式复合冠状动脉血运重建术（One-stop hybrid coronary revascularization）与coronary artery bypass grafting（CABG），PCI对比用于多支血管病变的三年随访结果。研究结果表明一站式复合冠状动脉血运重建术对多支血管病变血运重建后疗效良好，EuroSCORE 和SYNTAX 得分明显提高，有望成